Clinical trials: Gastrointestinal Infections
Hepatitis C Virus
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA < LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
- Trial name
- MAGNITUDE (NCT01741545)
- Testing
- Pegylated-Interferon-lambda, Ribavirin, Daclatasvir
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 71 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C, Decompensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.
- Conditions
- Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus
- Trial name
- TURQUOISE-CPB (NCT02219477)
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 36 people
- Sponsor
- AbbVie
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.
- Trial name
- ENDURANCE-2 (NCT02640482)
- Testing
- ABT-493/ABT-530
- Volunteers
- 304 people
- Sponsor
- AbbVie
HIV, Hepatitis C
Criminal Justice Coordinated Transitional Care
This project aims to enroll 220 incarcerated individuals living with HIV, Hepatitis C (HCV), or history of substance misuse preparing for release into a pilot implementation study to test the feasibility and acceptability of an…
- Conditions
- HIV, Hepatitis C, Substance Use Disorders
- Trial name
- CJC-TraC (NCT05376371)
- Testing
- CJC-TraC
- Where
- 2 sites in United States
- Volunteers
- 219 people
- Sponsor
- University of Wisconsin, Madison
Chronic Hepatitis C
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Chronic hepatitis C virus (HCV) infection is common in dialysis patients. Interferon (IFN)-based treatment for chronic hepatitis C has been the mainstay therapy in immunocompetent patients.
- Trial name
- NCT00491244
- Testing
- Peginterferon alfa-2a and ribavirin, Peginterferon alfa-2a
- Where
- Taiwan
- Volunteers
- 377 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C, Chronic
Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection
This study examined the influence of ribavirin on the initial virological response in treatment-naïve participants with chronic hepatitis C, genotype 1.
- Trial name
- NCT02716779
- Testing
- Pegylated Interferon (PEG-IFN) alfa-2a, Ribavirin
- Where
- 5 sites in Germany
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
HCV Infection
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
This study will evaluate the effect of sofosbuvir (SOF)/velpatasvir (VEL)/voxilaprevir (VOX) fixed-dose combination (FDC) + voxilaprevir on the pharmacokinetics (PK) of a representative hormonal contraceptive medication…
- Trial name
- NCT02533427
- Testing
- SOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol
- Where
- New Zealand
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
Eltrombopag Phase III Study In Chinese Chronic ITP Patients
This randomized, double-blind and open-label phase III study aimed to determine the efficacy, tolerance and safety of eltrombopag in Chinese chronic primary immune thrombocytopenia (ITP) adult subjects.
- Trial name
- NCT01762761
- Testing
- eltrombopag
- Where
- 18 sites in China
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Chronic, Hepatitis C
Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)
The objective of the study is to evaluate, in each group, the number of participants who achieve rapid virological response (RVR) after 4 weeks treatment with PegIntron and Rebetol.
- Trial name
- APEGIN (NCT00724854)
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 1,146 people
- Sponsor
- Merck Sharp & Dohme LLC
Appendicitis, Perforated Appendicitis
Optimal Care of Complicated Appendicitis
When the appendix becomes infected and inflamed, it is called appendicitis. Sometimes, if the infection and inflammation get worse, the appendix can die or burst, leading to a larger infection or even pus pockets around the…
- Conditions
- Appendicitis, Perforated Appendicitis, Ruptured Appendicitis, Complicated Appendicitis
- Trial name
- NCT03159754
- Testing
- Early Appendectomy, Interval Appendectomy, Antibiotics
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Hepatitis C Virus
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
The purpose of this study in HCV genotype 4-infected participants with compensated cirrhosis is to assess the safety and to compare the percentage of participants achieving a 12-week sustained virologic response (SVR12), [HCV…
- Trial name
- AGATE-1 (NCT02265237)
- Testing
- ombitasvir/paritaprevir/ritonavir, ribavirin
- Volunteers
- 184 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
Multidisciplinary Support Program in Chronic Hepatitis C
Adherence to antiviral treatment in chronic hepatitis C (CHC) is an important factor to achieve sustained virological response (SVR).
- Trial name
- NCT01850745
- Testing
- Multidisciplinary support program
- Where
- Spain
- Volunteers
- 447 people
- Sponsor
- Parc de Salut Mar
Hepatitis B, Hepatitis A
Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc
The focus of this study is to evaluate how risk factors like age, gender, body mass index, smoking, alcohol consumption, etc. can influence immune response when subjects are vaccinated with GSK Biologicals' combined hepatitis…
- Trial name
- NCT00289731
- Testing
- TWINRIX™, Engerix™-B, HAVRIX™
- Where
- 9 sites in Belgium, Czechia and 1 more
- Volunteers
- 596 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anal Cancer, High-grade Squamous Intraepithelial Lesion
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
The randomized phase of the trial compared topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL).
- Conditions
- Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
- Trial name
- ANCHOR (NCT02135419)
- Testing
- imiquimod, fluorouracil, infrared photocoagulation therapy
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 4,446 people
- Sponsor
- AIDS Malignancy Consortium
Hepatitis C
Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic…
- Trial name
- NCT01858766
- Testing
- SOF, VEL, RBV
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 379 people
- Sponsor
- Gilead Sciences
Hepatitis B
Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)
This study is performed to evaluate the persistence of anti-hepatitis B surface antigen (HBs) antibodies up to 16, 17, 18, 19 and 20 years after administration of the first dose of the study vaccine, Engerix-B™.
- Trial name
- NCT00240539
- Testing
- Blood sampling
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Malignancies
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
- Trial name
- NCT03241173
- Testing
- INCAGN01949, Nivolumab, Ipilimumab
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- Incyte Biosciences International Sàrl
Hepatitis B, Chronic Hepatitis B Atypical
Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection
To examine the safety and tolerability of IONIS-HBVRx administration to treatment-naive patients with chronic hepatitis B virus infection
- Trial name
- NCT02981602
- Testing
- IONIS-HBVRx
- Where
- 7 sites in Hong Kong, South Korea
- Volunteers
- 31 people
- Sponsor
- GlaxoSmithKline
Hepatitis C
Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals
To compare the effectiveness of a patient-centered, opiate agonist treatment (OAT)-integrated telemedicine-based approach for management and delivery of hepatitis C virus (HCV) treatment to persons with substance use disorders…
- Trial name
- NCT02933970
- Testing
- Telemedicine
- Where
- United States
- Volunteers
- 602 people
- Sponsor
- Andrew Talal
Hepatitis C, Chronic
Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)
The study is designed as a retrospective data review of medical records from participants selected from specialist secondary and tertiary care centers across the United Kingdom (UK), specializing in Hepatitis C treatment.
- Trial name
- NCT00724373
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 442 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.